New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Psyence Biomedical Ltd.

PBM

Healthcare Biotechnology

2.97 0.11 +3.85%

After hours trading: 3.01, up 1.35%, last trade Fri 4:09pm Eastern.

Market cap
$10.9M
P/E
0.1×
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
—
Net debt / EBITDA
1.2×
Payout ratio
—

Capital & Financial Ratios $m

Size
Market Cap 11
Revenue ttm —
Net income ttm 3
Free cash flow ttm (8)
Net debt Q (7)
Valuation
P/E 0.1
Forward P/E e —
Price / sales —
Forward P/S e Powerpack
Price / FCF n/m
Price / book 0.1
Financial health
Current ratio Q 8.1 (at or above 1.5: strong)
Debt / equity Q n/m
Interest coverage Q (538.0)
Growth
Revenue growth e —
EPS growth e —
EPS growth e —
EPS growth, 5 yrs e —
Insiders
Owned by insiders 0.0%

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates; n/m is not meaningful, as a P/E on a loss. How we judge →

Compound annual growth

10y 5y 3y
Sales — — —
Cash Flow — — —
Earnings — — —
Book Value — — —

Valuation

P/E against its own 10 years 5.62%
10-year low 10-year high
P/B against its own 10 years 21.08%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

1Buy 2 3Hold 4 5Sell

Ten years at a glance

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue — — — — — — — — — — — — — — —
Gross margin, % — — — — — — — — — — —
EBT — — — — 8 8 (51) (51) 1 (7) n/m
EBT margin, % — — — — — — — — — — —
Net income 0 — — — 8 8 0 (51) 1 (7) n/m
Per share, $
Per share, $ Revenue — — — — — — — — — — —
Earnings — — — — 0.25 0.25 (6.14) (29,211.54) 32.75 (12.56) n/m
Cash flow — — — — (0.03) (0.02) — (1,732.59) (120.85) (14.74) n/m
Capex — — — — 0.00 0.00 — (3.35) (0.32) 0.00 n/m
Free cash flow — — — — (0.03) (0.02) — (1,735.94) (121.17) (14.74) n/m
Book value — — — — 7.24 7.49 (1.32) (6,454.41) 217.54 30.68 +33.5%
Shares, m — — — — 33 33 8 0 0 1 (55.8%)
Valuation, ×
Valuation, × P/E — — — — — — — — — — —
P/S — — — — — — — — — — —
P/B — — — — — — — — — — —
EV/Sales — — — — — — — — — — —
EV/FCF — — — — — — — — — — —
Cash, $m
Cash, $m Operating cash flow — — — — (1) (1) — (3) (4) (8) n/m
Capex — — — — — — — 0 0 0 (81.3%)
Free cash flow — — — — (1) (1) — (3) (4) (8) n/m
Balance, $m
Balance, $m Working capital — — — — 1 (13) (11) (11) 6 8 +56.5%
Net debt — — — — (1) 0 (1) (1) (6) (7) n/m
Shareholders’ equity — — — — 237 245 (11) (11) 7 17 (41.0%)
Returns, %
Returns, % ROA — — — — 6.42 3.11 (39.34) (4,518.56) 23.95 (55.75) (62.2) pt
ROIC — — — — — — 0.00 0.00 (415.57) (41.24) (41.2) pt
ROE — — — — — 3.33 (54.66) 149.52 (47.61) (58.62) (61.9) pt
People
People Employees — — — — — — — 10 12 12 +9.5%
Revenue/emp, $m — — — — — — — — — — —
Negative figures in brackets.
estimates

All 10 years →

Psyence Biomedical Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
JSPR Jasper Therapeutics, Inc. $11.9M — (loss-making) — — n/m +67.81% (above 0%: growing) 0.09% (1,802.16%) Compare
BCDA BioCardia, Inc. $11.7M — (loss-making) — (loss-making) −93.02% (below 0%: shrinking) n/m −2.93% (below 0%: shrinking) 100.00% (54,966.67%) Compare
PASG Passage Bio, Inc. $11.6M — (loss-making) — — n/m +17.68% (above 0%: growing) 0.00% — Compare
AEON AEON Biopharma, Inc. $11.2M — (loss-making) — — n/m −120.53% (below 0%: shrinking) — — Compare
PBM Psyence Biomedical Ltd. $10.9M 0.1× — — n/m −1,628.07% (below 0%: shrinking) — —
RADX Radiopharm Theranostics Limited - Sponsored ADR $10.6M — — — — — — — Compare
HIND Vyome Holdings, Inc. $10.2M — (loss-making) — (loss-making) +67.63% (above 0%: growing) n/m +63.50% (above 0%: growing) 46.21% (1,760.52%) Compare
LSTA Lisata Therapeutics, Inc. $9.8M — (loss-making) — (loss-making) — n/m −279.44% (below 0%: shrinking) 100.00% (3,080.00%) Compare
BIVI BioVie Inc. $9.8M — (loss-making) — — n/m +3.92% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $10.9M — — — — +3.92% 23.15% (1,802.16%)

All 621 Biotechnology stocks →

Psyence Biomedical Ltd. (PBM) Latest News

20 more headlines
All PBM news, as stories →
stockrow.com/PBM · For information only; not investment advice. · © 2026 stockrow.com